- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Extensive-stage small cell lung cancer with progression on or after platinum-based chemotherapy
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 – May 2026 PBAC Meetings - (PDF)
- Public Summary Document (PSD) March 2026 – May 2026 PBAC Meetings - (DOCX)
Tarlatamab – March 2026 – May 2026
Powder for injection 1 mg, Powder for injection 10 mg
Last updated
24 April 2026